NetZealous LLC DBA GlobalCompliancePanel, Courtyard Seattle Sea-Tac Area 16038 West Valley Highway Tukwila Washington 98188 USA
Course "DESIGNING A PHARMACEUTICAL QUALITY SYSTEM: An in-depth examination of ICH Q10 and the companion documents (ICH Q8, Pharmaceutical Development and ICH Q9, Quality Risk Management), to establish a robust, globally-required Pharmaceutical Quality System" has been pre-approved by RAPS as eligible for up to 12 credits towards a participant's RAC recertification upon full completion.
The Purpose of this Course is to Review ICH Q10, which is a Document developed by the 3 Countries Comprising ICH (Us, Eu, Japan). ICH Q10 is for the Development of a Pharmaceutical Quality System, In Conjunction with the Companion Documents, ICH Q8, Pharmaceutical Development and ICH Q9, Quality Risk Management. In Addition to the Members of ICH (Us, Eu And Japan), Many Other Groups were involved in the Expert Working Committees that were involved in the Development of these Documents, Etc. Therefore, establishing a Pqs, Implementation and use throughout the Lifecycle of the Product (From Development to Product Discontinuation), Along with use of the ICH Q8 and ICH Q9 Companion Documents, is a Global Expectation of Regulatory Authorities. The Information that is contained within these Documents (Such as Module 3 Section Regarding Pharmaceutical Development and Justification of Product Development) are necessary for Regulatory Submission of New or Modified Products, Including Information Required for the Common Technical Document (The Regulatory Submission Requirements for New Products (of Chemical and Biological/Biotechnological Origin). In Addition, We will discuss the Development of the Drug Substance during this Course (ICH Q7 and ICH Q11), which is also a required part of the Regulatory Submission/Marketing Application, which requires a History, Justification, etc. of the Design and Development of the Drug Substance (Or API), In Addition to the Drug Product.
Why should you attend:
Manufacturer’s and Sponsors, as well as Contract Manufacturing Organizations should attend because establishing, implementing and maintaining a PQS across the Product Lifecycle (from development to product discontinuation) is a global expectation. Global Agencies (including FDA) are conducting regulatory audits against the PQS, and implementation of the PQS in conjunction with the documents that ICH created to meet the objectives of the PQS (ICH Q8, pharmaceutical development and quality risk management) is a global expectation. The benefits of establishing a PQS beyond the fact that it is an expectation include being able to establish a design space, which will allow Companies to make changes within the design space, without a requirement for a post-approval regulatory filing, therefore allowing Science and Risk based Changes that do not have to be filed if they stay in the design space. Other benefits, along with requirements, accompany the implementation of a Pharmaceutical Quality System (PQS).
Who will benefit:
- Product Development Personnel (Formulation scientists, Formulation chemists, etc. or Geneticists, R & D Scientists
- Process Development Personnel
- Technology Transfer personnel
- Validation Engineers/Validation Manager
- Quality Engineers
- Quality Management
- Analytical Services
- Regulatory Affairs and CMC personnel
Day 1 Schedule
Brief overview of ICH-30 minutes, description of the Pharmaceutical Quality System, per Q10, including objectives, background, enablers, definition of stages of Product Lifecycle and what activities constitute each stage.
Continue Review of Pharmaceutical Quality System, including elements, such as CAPA, Change Management, Process Performance and Product Quality Monitoring System, and Management Review of Process Performance and Product Quality.
Continue review of Pharmaceutical Quality System, including review of application/use of ICH Q10 pqs elements and Management responsibilities and encouraging the use of Science and Risk-based approaches at each lifecycle stage.
Examples of application of elements across the Lifecycle of the Product. Also, use of the Companion Documents, as ICH Q10 was designed to be used with ICH Q8, product development and ICH Q9, Quality Risk Management and talk about how they operate together.
Day 2 Schedule
Brief overview of ICH Q7, GMPS for APIs. Discussion of ICH Q11, Development and Manufacture of Drug Substances (Chemical entities and Biotechnological/Biological entities).
Discussion of ICH Q8, Pharmaceutical Development, including traditional and enhanced approaches to development, establishing Manufacturing process, Process parameters, introduction to Quality Risk Management for Product and Process Development. Will discuss both Drugs from Chemical entitites as well as Biotechnological/Biological entities.
More discussion of Quality Risk Management and relation of how to use these 3 documents for a Pharmaceutical Quality System (as ICH intended them to be used). Discussion of design space.
More discussion of design space, and establishing in regulatory filing (existing and new products) and the regulatory benefits of establishing a PQS, in conjunction with ICH Q8, and Q9, regulatory benefits of establishing a design space, as far as post-approval filings, and benefits of establishing and maintaining a Pharmaceutical Quality System across Product Lifecycle and benefits as far as Risk Based Regulatory Audits, etc.
President/CEO, Cooke Consulting Inc.
Stephanie Cooke, is the President/CEO of Cooke Consulting, Inc. Stephanie uses her roughly 20 years of experience to provide global consulting services in various areas of Regulatory Affairs, Quality Assurance and validation for pharmaceutical, biological/biotech products, medical device, combination drug/device and nutraceutical firms. Her broad-based experience includes preparation of regulatory dossiers for human and animal pharmaceutical (chemical entities and biologically-based drugs), biotech products, drug/device combination products and medical devices in all stages of development (INDs, NDAs, BLAs, post-marketing supplements such as CBEs, Prior approval supplements, orphan drug designation and related submissions, 510ks, PMAs and HDEs).
Location: Seattle, WA Date: April 26th & 27th, 2018 and Time: 9:00 AM to 6:00 PM
Venue: Courtyard Seattle Sea-Tac Area 16038 West Valley Highway Tukwila Washington 98188 USA
Price: $1,295.00 (Seminar Fee for One Delegate)
Register for 5 attendees Price: $3,885.00 $6,475.00 You Save: $2,590.00 (40%)*
Register for 10 attendees Price: $7,122.00 $12,950.00 You Save: $5,828.00 (45%)*
Register now and save $200. (Early Bird)
Until March 20, Early Bird Price: $1,295.00 From March 21 to April 23, Regular Price: $1,495.00
Sponsorship Program benefits for “Quality Assurance Auditing for FDA Regulated Industry” seminar
At this seminar, world-renowned FDA Regulated Industry subject matter experts interact with CXO’s of various designations. Executives who carry vast experience about FDA Regulated Industry and Experts get down to discussing industry-related best practices, regulatory updates, changes in technologies, and much more relating to FDA Regulated Industry.
As a sponsor of these seminars, you get the opportunity to have your product and company reach out to C-Level executives in FDA Regulatory -related industries and become known among these elite executives and subject matter experts. Apart from being seen prominently at these globally held seminars, you also get talked about frequently in our correspondences with our experts and these participants.
For More Information- https://www.globalcompliancepanel.com/control/sponsorship
Contact us today!
NetZealous LLC DBA GlobalCompliancePanel
Toll free: +1-800-447-9407
Registration Link - Registration Link - https://www.globalcompliancepanel.com/control/globalseminars/~product_id=901546SEMINAR?april-seo-2018
Follow us on LinkedIn: https://www.linkedin.com/company/globalcompliancepanel/
Like us our Facebook page: https://www.facebook.com/TrainingsAtGlobalCompliancePanel/
Follow us on Twitter: https://twitter.com/GCPanel